Different strategies for cancer treatment: Mathematical modelling
暂无分享,去创建一个
[1] A. Buzaid,et al. Practical guidelines for the management of biochemotherapy-related toxicity in melanoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] V. Engelhard,et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] W. Solbach,et al. T‐T Cell Interactions during Cytotoxic T Lymphocyte (CTL) Responses: T Cell Derived Helper Factor (Interleukin 2) as a Probe to Analyze CTL Responsiveness and Thymic Maturation of CTL Progenitors , 1980, Immunological reviews.
[4] S. Rosenberg,et al. Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated Lymphocytes , 1986 .
[5] Karol Sikora,et al. ONCOGENES , 1983, The Lancet.
[6] A. Diefenbach,et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity , 2001, Nature.
[7] Nicola Bellomo,et al. A Survey of Models for Tumor-Immune System Dynamics , 1996 .
[8] L. D. de Pillis,et al. A cellular automata model of tumor-immune system interactions. , 2006, Journal of theoretical biology.
[9] M. Nowak,et al. Oncogenes, anti-oncogenes and the immune response to cancer : a mathematical model , 1992, Proceedings of the Royal Society of London. Series B: Biological Sciences.
[10] A. Radunskaya,et al. Mixed Immunotherapy and Chemotherapy of Tumors: Modeling, Applications and Biological Interpretations , 2022 .
[11] Ami Radunskaya,et al. A mathematical tumor model with immune resistance and drug therapy: an optimal control approach , 2001 .
[12] E. Rosenbaum,et al. Everyone's Guide to Cancer Supportive Care: A Comprehensive Handbook for Patients and Their Families , 2005 .
[13] E. Bissonette,et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] D. Longo,et al. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Lefever,et al. A kinetic approach to the immunology of cancer: stationary states properties of effector-target cell reactions. , 1978, Journal of theoretical biology.
[16] Keith L Black,et al. Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination , 2004, Clinical Cancer Research.
[17] Ami Radunskaya,et al. The dynamics of an optimally controlled tumor model: A case study , 2003 .
[18] K. Lillehei,et al. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. , 2003, Cancer control : journal of the Moffitt Cancer Center.
[19] S. Kamidono,et al. Rejection of Mouse Renal Cell Carcinoma Elicited by Local Secretion of Interleukin‐2 , 1996, Japanese journal of cancer research : Gann.
[20] Q. Zeng,et al. Generation of PRL-3- and PRL-1-Specific Monoclonal Antibodies as Potential Diagnostic Markers for Cancer Metastases , 2005, Clinical Cancer Research.
[21] Mark A J Chaplain,et al. Mathematical modelling of the spatio-temporal response of cytotoxic T-lymphocytes to a solid tumour. , 2004, Mathematical medicine and biology : a journal of the IMA.
[22] D. Farquhar,et al. Mechanism of action and pharmacology studies with DTIC (NSC-45388). , 1976, Cancer treatment reports.
[23] S N Gardner,et al. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. , 2000, Cancer research.
[24] A. Buzaid,et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] T. Wheldon. Mathematical models in cancer research , 1988 .
[26] R. Scheuermann,et al. Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. , 1999, Journal of immunology.
[27] P Hogeweg,et al. Macrophage T lymphocyte interactions in the anti-tumor immune response: a mathematical model. , 1985, Journal of immunology.
[28] D. Kirschner,et al. A mathematical model of tumor-immune evasion and siRNA treatment , 2003 .
[29] T. Moritz,et al. Models for Immunotherapy and Cancer Vaccines , 2007 .
[30] Markus R. Owen,et al. MATHEMATICAL MODELLING OF MACROPHAGE DYNAMICS IN TUMOURS , 1999 .
[31] Alan S. Perelson,et al. Recruitment Times, Proliferation, and Apoptosis Rates during the CD8+ T-Cell Response to Lymphocytic Choriomeningitis Virus , 2001, Journal of Virology.
[32] Trachette L. Jackson,et al. Vascular tumor growth and treatment: Consequences of polyclonality, competition and dynamic vascular support , 2002, Journal of mathematical biology.
[33] A. Perelson,et al. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.
[34] Miss A.O. Penney. (b) , 1974, The New Yale Book of Quotations.
[35] K J O'Byrne,et al. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. , 2000, European journal of cancer.
[36] M. O.,et al. Pattern Formation and Spatiotemporal Irregularity in a Model for Macrophage – Tumour Interactions , 1997 .
[37] A. Buzaid. Strategies for combining chemotherapy and biotherapy in melanoma. , 2000, Cancer control : journal of the Moffitt Cancer Center.
[38] Stephanie Forrest,et al. A stochastic model of cytotoxic T cell responses. , 2004, Journal of theoretical biology.
[39] A. Murugan,et al. Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls. , 2007, Mathematical biosciences.
[40] C. Giachino,et al. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity? , 2005, Pigment cell research.
[41] G. Griffiths,et al. Development of humanized antibodies as cancer therapeutics. , 2005, Methods.
[42] M. Sznol,et al. Antibodies and Recombinant Cytokines , 2005 .
[43] M. Chaplain,et al. Travelling-wave analysis of a model of the immune response to cancer. , 2004, Comptes rendus biologies.
[44] J. Trempe. Molecular biology of the cell, 3rd edition Bruce Alberts, Dennis Bray, Julian Lewis, Martin Raff, Keith Roberts and James D. Watson, Garland Publishing, 1994, 559.95 (xiii + 1294 pages), ISBN 0-815-31619-4 , 1995, Trends in Endocrinology & Metabolism.
[45] D. Kirschner,et al. Modeling immunotherapy of the tumor – immune interaction , 1998, Journal of mathematical biology.
[46] Jon Ernstberger,et al. OPTIMAL CONTROL APPLIED TO IMMUNOTHERAPY , 2003 .
[47] V. Osipov,et al. Modeling of anti-tumor immune response: immunocorrective effect of weak centimeter electromagnetic waves , 2005, q-bio/0506006.
[48] Zhiwei Hu,et al. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. , 1999, Proceedings of the National Academy of Sciences of the United States of America.